Last updated: February 28, 2026
What is the Drug and Its Market Position?
NDC 68546-0170 corresponds to Galcanezumab, marketed as Emgality. It is a calcitonin gene-related peptide (CGRP) antagonist approved by the FDA in 2018 for the preventive treatment of migraines in adults.
Galcanezumab competes within a niche drug class targeting migraine prevention. Key competitors include Erenumab (Aimovig), Fremanezumab (Ajovy), and Eptinezumab (Vyepti). The drug’s market share depends on prescriber adoption, insurance coverage, and patient preference.
Market Size and Growth Drivers
The migraine prophylaxis market has expanded due to increased awareness and diagnosis.
- Global migraine market valuation (2022): Approximately $3.2 billion.
- Projection (2027): Expected to reach $5.1 billion at a CAGR of 8.3% (Grand View Research).
- US-specific segment: Accounted for around $1.8 billion in 2022, with growth driven by expanding indications and payer acceptance.
Key factors influencing growth:
- Rising prevalence of migraine: Estimated 39 million Americans affected.
- Expanded prescribing guidelines: Recent updates support CGRP inhibitors as first-line options.
- Payor coverage policies: Increasing reimbursement inclusion for CGRP therapies.
Pricing Analysis
Pricing models for branded migraine drugs reflect monthly costs and insurance negotiations.
- Average wholesale price (AWP): Approx. $800 to $900 per 120 mg dose.
- Average payer net price: Estimated at $650 to $750 due to discounts and rebates.
- Patient copay: Typical out-of-pocket costs range from $25 to $75 per dose, depending on insurance.
Galcanezumab dosing: Monthly subcutaneous injections, with each dose containing 120 mg.
Price Comparison with Competitors
| Drug |
Monthly Cost (Estimated) |
Dosing |
Market Position |
| Galcanezumab |
$650 - $750 |
120 mg once monthly |
Moderate market share |
| Erenumab |
$700 - $800 |
70 mg or 140 mg once monthly |
Largest market share |
| Fremanezumab |
$650 - $750 |
225 mg quarterly or 675 mg monthly |
Similar pricing, flexible dosing |
| Eptinezumab |
$950 - $1,050 |
300 mg quarterly |
More expensive, IV-administered |
Price Projection Trends (2023-2027)
- Price stabilization: For branded biologics, prices are expected to remain relatively stable due to patent protections.
- Rebate dynamics: Insurance rebates will likely sustain net pricing downward pressure.
- Potential discounts: Biosimilar competition is unlikely within the next five years, delaying significant price reductions.
| Year |
Estimated Average Monthly Price |
Notes |
| 2023 |
$700 |
Current pricing in most payers |
| 2024 |
$700-$730 |
Slight increase anticipated with inflation; rebates apply |
| 2025 |
$700 |
Price stability expected |
| 2026 |
$700 |
Biosimilars unlikely; patent extends until 2028 |
| 2027 |
$700 |
Potential for negotiated discounts |
Key Market Trends and Considerations
- Patent expiry: Not until 2028; no biosimilar competition predicted before then.
- Reimbursement policies: Payer shifts favor cost-effective options, potentially pressure pricing.
- Innovation: New delivery methods or dual therapy formulations could alter market dynamics.
- Regulatory activity: Expanded approvals for broader indications may boost sales volume but could impact pricing strategies.
Regulatory and Patent Landscape
- Patent protection: Valid until 2028; extensions possible for formulation or manufacturing patents.
- Legal challenges: Patent disputes with biosimilar developers are possible near expiration.
- FDA approvals: Currently limited to migraine prevention; future indications could impact market size further.
Summary
Galcanezumab (NDC 68546-0170, Emgality) maintains a stable pricing environment, with monthly costs around $700-$750. The overall market is growing, driven by migraine prevalence and increased reach of CGRP inhibitors. Absence of biosimilars until at least 2028 supports pricing stability, but reimbursement pressures may influence net prices.
Key Takeaways
- The migraine prophylactic market is expanding at 8.3% CAGR; Galcanezumab is a mid-market share product.
- Current retail price estimates hover around $700 monthly; discounts and rebates reduce payer costs.
- Patent expiry in 2028 suggests limited short-term price erosion.
- Competition from similar biologics remains stiff until biosimilar entry.
- Market growth relies heavily on expanding indications and payer acceptance.
FAQs
Q1: How does the price of Galcanezumab compare with competitors?
It is generally similar to Fremanezumab and slightly below Erenumab, with monthly costs around $700-$750.
Q2: What impact will biosimilars have after patent expiration?
Biosimilars could reduce prices by 20-40%, depending on market adoption and regulatory approval.
Q3: Are insurance companies likely to cover Galcanezumab widely?
Yes, coverage is increasing, especially as guidelines favor CGRP inhibitors for migraine prevention.
Q4: What pricing risks exist for manufacturers?
Reimbursement reductions, generic competition, and payer pressure could lead to lower net prices.
Q5: How might future regulatory changes influence pricing?
More streamlined approval processes or expanded indications could increase sales volume without significantly changing prices.
References
- Grand View Research. (2022). Migraine market size, trends, and forecasts. [Online] Available at: https://www.grandviewresearch.com/industry-analysis/migraine-market
- U.S. Food and Drug Administration. (2018). FDA approves first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention. [Online]
- IQVIA. (2022). Pharmaceutical pricing and reimbursement landscape. [Online]
